[Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months]

A Mairovitz; E Staub; H Le Floch; F Rivière; A Bonnichon; J Margery; F Vaylet

doi:10.1016/j.pneumo.2009.06.002

[Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months]

Rev Pneumol Clin. 2009 Oct;65(5):318-21. doi: 10.1016/j.pneumo.2009.06.002. Epub 2009 Aug 29.

[Article in French]

Authors

A Mairovitz¹, E Staub, H Le Floch, F Rivière, A Bonnichon, J Margery, F Vaylet

Affiliation

¹ Service de Pneumologie, HIA de Percy, 101, Avenue Henri-Barbusse, BP 406, 92141, Clamart Cedex, France. alexamairovitz@hotmail.com

PMID: 19878809
DOI: 10.1016/j.pneumo.2009.06.002

Abstract

The prognosis of stage IV nonsmall cell lung cancer, in particular with brain metastases, is extremely poor. The impact of targeted therapy, in particular erlotinib, on patient survival has still not been determined. The authors report the case of a patient diagnosed with nonsmall cell lung cancer with bone and brain metastases. The patient presented a complete cerebral response for 17 months with erlotinib prescribed as a third line therapy.

Publication types

Case Reports
English Abstract

MeSH terms

Antineoplastic Agents / therapeutic use*
Brain Neoplasms / drug therapy*
Brain Neoplasms / radiotherapy
Brain Neoplasms / secondary*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / radiotherapy
Carcinoma, Non-Small-Cell Lung / secondary
Disease Progression
Disease-Free Survival
Erlotinib Hydrochloride
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology*
Lung Neoplasms / radiotherapy
Middle Aged
Prognosis
Protein Kinase Inhibitors / therapeutic use*
Quinazolines / therapeutic use*

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Quinazolines
Erlotinib Hydrochloride